Home | Site Index | Contact Us
	Home >> Investor Relations >> Investor Relations Home
	Investor Relations Home     Stock Chart     News Releases     Financial Reports     Events and Presentations     Annual Reports     Analyst Coverage     SEC Filings     Advanced Fundamentals     Corporate Governance               Shareholder Services     Information Request     E-mail Alerts Corporate Profile Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops and markets prescription and non prescription pharmaceutical products principally in the areas of neurology and dermatology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in neurology and dermatology. Valeant’s strategic markets focus primarily in the United States, Canada, Mexico, Brazil and Australia. Headquartered in Orange County, California, Valeant has approximately 2,600 employees worldwide and is led by J. Michael Pearson, Chairman and CEO. Investor Fact Sheet 2008 Current Webcasts and Presentations Webcast Valeant Pharmaceuticals International at Lazard Capital Markets 5th Annual Healthcare Conference (Live) 11/19/08 at 11:00 a.m. ET Webcast Valeant Pharmaceuticals International at Credit Suisse Group Healthcare Conference (Replay) 11/14/08 at 9:30 a.m. MT Webcast Q3 2008 Valeant Pharmaceuticals International Earnings Conference Call (Replay) 11/06/08 at 10:00 a.m. ET Webcast Valeant Pharmaceuticals International at UBS Global Life Sciences Conference (Replay) 09/24/08 at 11:00 a.m. ET Contacts General Investor Relations ir@valeant.com Phone: (949) 461-6178 Fax: (949)461-6636 Laurie W. Little Vice President, Investor Relations Phone: (949) 461-6002 Proxy and Stock Certificate Questions American Stock Transfer and Trust Company 6201 15th Avenue Brooklyn, NY 11219 www.amstock.com (800) 937-5449 Stock Quote VRX (common stock) Exchange NYSE (US Dollar) Price $18.54 Change (%)   0.25 (1.37%) Volume 12,964 Data as of 11/18/08 9:42 a.m. ET Minimum 20 minute delay Refresh quote Recent News More >> Date Title   11/14/08 Valeant Pharmaceuticals Acquires DermaTech 11/12/08 Valeant Pharmaceuticals to Present at Lazard Capital Markets 5th Annual Healthcare Conference 11/07/08 Valeant Pharmaceuticals to Present at 2008 Credit Suisse Phoenix Health Care Conference 11/06/08 Valeant Pharmaceuticals Reports Third Quarter Financial Results Receive E-mail Alerts Sign up to receive e-mail alerts whenever Valeant Pharmaceuticals International posts new information to the site. Just enter your e-mail address and click Submit. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
	TARIBAVIRIN and RETIGABINE are products in clinical development. None of them have been found to be safe or effective for the treatment of any disease or illness. They may not be sold or promoted in the United States unless and until they are approved by the FDA. Similar restrictions apply in other countries.
	© Valeant Pharmaceuticals International 2004 Legal and Privacy Statement